UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice.

作者: Yuji Basaki , Kazutaka Miyadera , Yuji Yamada , Kazuhiko Yonekura , Soko Okabe

DOI:

关键词:

摘要: UFT, an anticancer agent that is composed of tegafur (FT) and uracil at a molar ratio 1:4, widely used in clinical practice Japan to treat cancer patients requiring long-term chemotherapy, it associated with few side effects, if any. In this study, we have evaluated the inhibitory effect UFT against RENCA cell-induced angiogenesis by dorsal air sac assay. Marked induced implantation chamber containing cells into mice. model, showed strong angiogenesis-inhibitory effect, whereas 5-fluorouracil (5-FU) doxifluridine were less effective. Additional experiments revealed FT be effective component UFT; remained ineffective inhibition angiogenesis. Moreover, found γ-hydroxybutyric acid γ-butyrolactone, metabolites FT, possess potent amplified when compounds are administered continuous infusion. This may reflect transition blood concentration each metabolite resulting from administration UFT. Similar results also obtained respect 5-FU. It was suggested has stronger than did other fluorinated pyrimidines, partly due its pharmacokinetic properties characterized maintaining higher long-lasting levels 5-FU effects derived UFT-specific metabolites.

参考文章(28)
R. H. Wiltrout, K. Volker, J. R. Ortaldo, J. M. Wigginton, M. J. Brunda, K. L. McCormick, W. E. Fogler, M. Watanabe, Regulation of local host-mediated anti-tumor mechanisms by cytokines: direct and indirect effects on leukocyte recruitment and angiogenesis. American Journal of Pathology. ,vol. 150, pp. 1869- 1880 ,(1997)
J Lai-Sim Au, Wolfgang Sadée, None, Activation of Ftorafur [R,S-1-(Tetrahydro-2-furanyl)-5-fluorouracil] to 5-Fluorouracil and γ-Butyrolactone Cancer Research. ,vol. 40, pp. 2814- 2819 ,(1980)
Debra Weinstat‐Saslow, Patricia S. Steeg, Angiogenesis and colonization in the tumor metastatic process: basic and applied advances. The FASEB Journal. ,vol. 8, pp. 401- 407 ,(1994) , 10.1096/FASEBJ.8.6.7513289
H Sonoo, H Saito, R B Dickson, H Fukumori, J Kurebayashi, N Unemi, M Nukatsuka, M Kurosumi, S Takeda, A Fujioka, Postsurgical oral administration of uracil and tegafur inhibits progression of micrometastasis of human breast cancer cells in nude mice. Clinical Cancer Research. ,vol. 3, pp. 653- 659 ,(1997)
P A Francis, J R Rigas, M G Kris, K M Pisters, J P Orazem, K J Woolley, R T Heelan, Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. Journal of Clinical Oncology. ,vol. 12, pp. 1232- 1237 ,(1994) , 10.1200/JCO.1994.12.6.1232
Eiki Gotohda, Masuo Hosokawa, Takao Kodama, Jitsuo Akiyama, Hiroshi Kobayashi, Tsugumichi Kawamura, Yuji Yamada, Effect of Normal Allogeneic Lymphoid Cell Transfer in Combination with Chemotherapy on a Transplantable Tumor in Rats Cancer Research. ,vol. 40, pp. 954- 958 ,(1980)
J. Thompson, K. Anderson, J. DiPietro, J. Zwiebel, M Zametta, W. Anderson, T Maciag, Site-directed neovessel formation in vivo Science. ,vol. 241, pp. 1349- 1352 ,(1988) , 10.1126/SCIENCE.2457952
Elizabeth C. Downs, Nancy E. Robertson, Terry L. Riss, Marian L. Plunkett, Calcium alginate beads as a slow-release system for delivering angiogenic molecules in vivo and in vitro. Journal of Cellular Physiology. ,vol. 152, pp. 422- 429 ,(1992) , 10.1002/JCP.1041520225
SD Ferrara, S Zotti, L Tedeschi, G Frison, F Castagna, L Gallimberti, GL Gessa, P Palatini, Pharmacokinetics of gamma-hydroxybutyric acid in alcohol dependent patients after single and repeated oral doses. British Journal of Clinical Pharmacology. ,vol. 34, pp. 231- 235 ,(1992) , 10.1111/J.1365-2125.1992.TB04129.X